Drug intelligence / Profile preview

WO533

Development stage: Phase 2
Lead developer: Dr August Wolff
Modality: Small Molecules
Administration: Vaginal

Overview

WO533 is an investigational **lactic acid-containing vaginal suppository** developed by Dr. August Wolff for local vaginal administration in postmenopausal women with vulvovaginal atrophy. It was evaluated in a prospective, open-label, single-center clinical study assessing efficacy and tolerability in vulvovaginal atrophy. The product is intended to provide local lactic acid exposure and support an acidic vaginal environment; no specific receptor-mediated molecular target has been publicly disclosed. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04222647))

Other names: WO 533WO533WO-533

Beyond the preview

Go deeper on WO533.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WO533.

Explore the full profile